Success Metrics

Clinical Success Rate
75.0%

Based on 12 completed trials

Completion Rate
75%(12/16)
Active Trials
3(12%)
Results Posted
67%(8 trials)
Terminated
4(15%)

Phase Distribution

Ph early_phase_1
4
15%
Ph not_applicable
4
15%
Ph phase_2
7
27%
Ph phase_1
1
4%
Ph phase_3
1
4%
Ph phase_4
8
31%

Phase Distribution

5

Early Stage

7

Mid Stage

9

Late Stage

Phase Distribution25 total trials
Early Phase 1First-in-human
4(16.0%)
Phase 1Safety & dosage
1(4.0%)
Phase 2Efficacy & side effects
7(28.0%)
Phase 3Large-scale testing
1(4.0%)
Phase 4Post-market surveillance
8(32.0%)
N/ANon-phased studies
4(16.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

70.6%

12 of 17 finished

Non-Completion Rate

29.4%

5 ended early

Currently Active

3

trials recruiting

Total Trials

26

all time

Status Distribution
Active(4)
Completed(12)
Terminated(5)
Other(5)

Detailed Status

Completed12
unknown5
Terminated4
Recruiting2
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
26
Active
3
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (16.0%)
Phase 11 (4.0%)
Phase 27 (28.0%)
Phase 31 (4.0%)
Phase 48 (32.0%)
N/A4 (16.0%)

Trials by Status

not_yet_recruiting14%
recruiting28%
terminated415%
unknown519%
completed1246%
active_not_recruiting14%
withdrawn14%

Recent Activity

Clinical Trials (26)

Showing 20 of 26 trialsScroll for more
NCT06468202Phase 4

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

Recruiting
NCT04479072Phase 4

Aspirin and Preeclampsia

Recruiting
NCT03771651Early Phase 1

Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube

Active Not Recruiting
NCT03590821Early Phase 1

Timed Aspirin Chronobiome Study

Not Yet Recruiting
NCT04295850

Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy)

Completed
NCT04243122Phase 2

Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients

Completed
NCT04031729Phase 1

Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease

Completed
NCT03961360Phase 2

Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida

Completed
NCT04153760Early Phase 1

Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

Completed
NCT04402385Phase 2

Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)

Terminated
NCT03649711Phase 3

Chronic Kidney Disease (CKD) Platelet Study

Completed
NCT04062032Phase 2

Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

Completed
NCT04066725Phase 2

Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

Completed
NCT04363840Phase 2

The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations

Withdrawn
NCT03433586Phase 4

COMT on Aspirin Platelets Effects (CAPE)

Unknown
NCT04059679Phase 4

Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy

Unknown
NCT03100123Early Phase 1

AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study

Terminated
NCT03424408Not Applicable

Serum Thromboxane B2 Assay as a Measure of Platelet Production in Healthy Volunteers Taking Aspirin

Completed
NCT03224923Phase 4

A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)

Terminated
NCT03726177Not Applicable

Aspirin for Prevention of Preeclampsia

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
26